Imetabolic Biopharma Corporation
Organisation
People
Sources: reporter.nih.gov
Grants and prizes
National Heart, Lung, and Blood Institute
R43, Therapeutic Approach to Clear sdLDL from Circulation, R43HL174270, US$299.5k, 2024–2026, 15 Sept 2024
National Heart, Lung, and Blood Institute
R43, Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation, R43HL170808, US$283.1k, 2023–2025, 30 Jun 2023
Sources: reporter.nih.gov